AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
iSpecimen Announces Completion of $4 Million Underwritten Offering, Plans to Use Proceeds for Marketing, Advertising, and Working Capital
ByAinvest
Friday, Jul 25, 2025 1:54 pm ET1min read
iSpecimen Inc. closed a $4 million underwritten public offering, selling 5.7 million shares of common stock at $0.70 per share. The company plans to use the net proceeds for marketing services, milestone payment, and working capital. WestPark Capital acted as the sole book-runner for the offering, which was conducted on a firm commitment basis. The securities were offered pursuant to a registration statement declared effective by the SEC.
iSpecimen Inc. (Nasdaq: ISPC) has successfully closed a $4 million underwritten public offering, selling 5,714,283 shares of its common stock at $0.70 per share. The company plans to allocate the net proceeds to marketing services, milestone payments, and working capital [1].The offering was conducted on a firm commitment basis, with WestPark Capital, Inc. acting as the sole book-runner. The securities were offered pursuant to a registration statement declared effective by the Securities and Exchange Commission (SEC) on July 23, 2025 [1].
iSpecimen Inc. is an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers. The company's proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations [1].
The company plans to use the net proceeds from the offering to pay $1,500,000 for marketing and advertising services to be provided by IR Agency LLC, $1,000,000 to fund the initial milestone payment under a definitive agreement with Sales Stack Solutions Corp., and the remainder for working capital and general corporate purposes [1].
The completion of this offering represents a significant milestone for iSpecimen Inc., providing much-needed capital to support its growth and expansion efforts. However, the low per-share price of $0.70 suggests challenging financing circumstances for the company, reflecting the difficult fundraising environment for smaller biotech marketplace companies [2].
References:
[1] https://www.morningstar.com/news/globe-newswire/9499904/ispecimen-inc-announces-pricing-of-4-million-underwritten-offering
[2] https://www.stocktitan.net/news/ISPC/i-specimen-inc-announces-closing-of-4-million-underwritten-vb266yuxtjde.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet